Ion Beam Therapy Center, SAGA HIMAT Foundation, Tosu, Japan.
QST Hospital, National Institutes for Quantum and Radiological Sciences and Technology, Chiba, Japan.
In Vivo. 2021 Jul-Aug;35(4):2239-2245. doi: 10.21873/invivo.12496.
BACKGROUND/AIM: To evaluate treatment outcomes of carbon-ion radiotherapy for oropharyngeal non-squamous cell carcinoma at four carbon-ion facilities in Japan.
We retrospectively analyzed the cases of 33 patients with oropharyngeal non-squamous cell carcinoma who were treated with carbon-ion radiotherapy between November 2003 and December 2014.
The histology included adenoid cystic carcinoma (n=25) and mucosal malignant melanoma (n=4). No patients had T1 tumors; 23 had T4 tumors. The most-commonly prescribed dose was 57.6 Gy (RBE) in 16 fractions. The median follow-up period was 34.8 months (range=4.2-122.8 months). The 3-year local control and overall survival rates were 94.7% and 90.7%, respectively. There were no grade ≥4 acute adverse events. Only one patient experienced a grade ≥4 late adverse event. No patients experienced late adverse events related to swallowing or salivary function.
Carbon-ion radiotherapy appears to be a promising treatment option for oropharyngeal non-squamous cell carcinoma.
背景/目的：评估日本四家重离子设施治疗口咽非鳞状细胞癌的治疗效果。
我们回顾性分析了 2003 年 11 月至 2014 年 12 月期间接受重离子放疗的 33 例口咽非鳞状细胞癌患者的病例。
组织学包括腺样囊性癌（n=25）和黏膜恶性黑色素瘤（n=4）。没有 T1 期肿瘤患者；23 例 T4 期肿瘤患者。最常规定剂量为 57.6Gy（RBE），共 16 次。中位随访时间为 34.8 个月（范围 4.2-122.8 个月）。3 年局部控制率和总生存率分别为 94.7%和 90.7%。无≥4 级急性不良反应。仅有 1 例患者发生≥4 级迟发性不良反应。无患者出现与吞咽或唾液功能相关的迟发性不良反应。
重离子放疗似乎是口咽非鳞状细胞癌的一种有前途的治疗选择。
